IMAC Holdings, Inc. Announces Completion of Second Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
February 16, 2022 09:30 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the second cohort of its Phase 1 clinical trial for...
IMAC Holdings to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
January 05, 2021 09:00 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative...
IMAC Holdings Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson’s Disease
December 30, 2020 09:00 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn., Dec. 30, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative...